Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Mar 12, 2020 8:17pm
60 Views
Post# 30801961

RE:RE:Shiseido is sticking with RCH-01

RE:RE:Shiseido is sticking with RCH-01
Ingiboy wrote: Nice to see Replicel linking themselves to this hair regenerative medicine study done by Shiseido.  The only problem here is Shiseido is not in any way linking itself with Replicel . Replicel uses the term RCH-01 in it's tweet but on the website referring to the Hair Regenerative Medicine Shiseido states:
"Shiseido has been collaborating with University Hospitals on a clinical study on the establishment of “hair regenerative medicine technology” in Japan. "

Nowhere do the make any reference to "collaborating" with Replicel or do the mention RCH-01.

Oh well at least they will continue their reearch:
"A further clinical study aiming at practical application will be conducted in the future."


I doesn't appear that any revenue with generated....unfortunately.
Bullboard Posts